LCIS hormone receptor status

They didn't do hormone receptors on my LCIS and I don't recall anyone else here having theirs done either. The NCI new guidelines and recommendation is for Aromasin in menopausal women so that would certainly be standard of care, but I can't remember anyone else here using it in conjunction with Lupron, so don't know about that.

The fact that you had dvt with Tamox and can't take it would certainly seem to be a reasonable argument for the lupron combo.

Lekker, it is prescribed as prophylactic & that is standard of care for LCIS or ALH. I think the combo with the lupron is confusing the insurance company since the AIs are only given to menopausal women. AIs don't have the clotting risk that tamoxifen and Evista do. Since she had a clot on tamox they're giving her lupron so she can take the AI. Kind of an unusual situation.

I will not be holding my breath. 

I have certainly not looked everywhere, but I'm not aware of any trials that specifically looked at LCIS + an antihormonal (no matter which one).  For example, the STAR P-2 study, 9.2% of the participants had LCIS.  From the abstract, I can't tell if they analyzed the LCIS population separately.  Maybe the actual study says, but I can only find information about the group as a whole (9.2% LCIS patients plus 90.8% other.)  Having a significant family history could also have an influence on some LCIS patients and not other LCIS patients, which is not recorded in the abstract.

http://www.ncbi.nlm.nih.gov/pubmed/19213563

In this 2013 meta-analysis of chemoprevention, the trials they look at just specify if a group is at normal risk, higher risk +/- family history.  (In other words, these groups are not just women with LCIS or LCIS/ALH.) 

http://www.thelancet.com/journals/lancet/article/P...

In this article above, they  do state

We obtained individual participant data directly from the trial investigators, so they probably have data, but its not in the paper.  I've heard in some podcasts that some/all journals limit the length of articles, sometimes to 3000 words.I don't know if that is the case here.

Despite their effectiveness, SERMs have not been widely accepted as
breast cancer preventive drugs by high-risk women and their primary care
physicians, mainly because of concern about toxic effects and a
perceived unfavourable balance between benefits and harms.
Unfortunately, at the present time, none of these drugs are being
actively marketed for breast cancer prevention, and approval by the US
Food and Drug Administration or any other regulatory authority for this
indication will probably not be sought for lasofoxifene or arzoxifene

Since LCIS is unusual, they had to group many women who are at higher risk together to get significant results.  LCIS women in the STAR P-2 study could have had vastly different results than other high risk women in the group and not affect the overall numbers.

I was just curious & dug out my path report to see if the receptors were tested & I just didn't remember. They weren't. Just the e-cadherin testing & that my slides were presented at their breast board the next morning.

Good deal Mandy. At least a step in the right direction.